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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer, proving
difficult to manage clinically. Wnt-11, a developmentally regulated gene producing a secreted
protein, has been associated with various carcinomas but has not previously been studied in PDAC.
The present study aimed to elucidate these aspects first in vitro and then in a clinical setting in vivo.
Molecular analyses of Wnt-11 expression as well as other biomarkers involved qRT-PCR, RNA-seq
and siRNA. Proliferation was measured by MTT; invasiveness was quantified by Boyden chamber
(Matrigel) assay. Wnt-11 mRNA was present in three different human PDAC cell lines. Wnt-11 loss
affected epithelial-mesenchymal transition and expression of neuronal and stemness biomarkers
associated with metastasis. Indeed, silencing Wnt-11 in Panc-1 cells significantly inhibited their
Matrigel invasiveness without affecting their proliferative activity. Consistently with the in vitro data,
human biopsies of PDAC showed significantly higher Wnt-11 mRNA levels compared with matched
adjacent tissues. Expression was significantly upregulated during PDAC progression (TNM stage I to
II) and maintained (TNM stages III and IV). Wnt-11 is expressed in PDAC in vitro and in vivo and
plays a significant role in the pathophysiology of the disease; this evidence leads to the conclusion
that Wnt-11 could serve as a novel, functional biomarker PDAC.
Keywords: Wnt-11; pancreatic ductal adenocarcinoma; epithelial-mesenchymal transition; invasion
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the main form of pancreatic cancer and has one of
the highest death rates among human cancers with a 5-year survival of less than 4% [1–3]. The high
mortality rate is due mainly to difficulties in both diagnosis and treatment [2], as the disease is
relatively symptomless until the late stages. Carbohydrate antigen (CA) 19-9 is currently the only
available biomarker for PDAC; however, it is not reliable due to its poor sensitivity and specificity [4].
Moreover, Lewis antigen-negative individuals, who compose approximately 5%–10% of PDAC cases,
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are genetically unable to produce CA19-9 [4,5]. Recent studies have shown that the accuracy of CA19-9
may be increased by combining with other biomarkers, such as carcinoembryonic antigen (CEA)
and/or transforming growth factor beta (TGFβ) superfamily member, macrophage inhibitory cytokine
1 (MIC-1) [6–10]. There is a clear and significant unmet need to identify viable, functional biomarkers
of PDAC.
As regards therapy, ‘conventional’ treatments, such as surgery, radiation therapy, chemotherapy,
and more recently, immunotherapy, so far have shown an impact on progression of PDAC, but
this is still limited [11]. The most common chemotherapy regimen is FOLFIRINOX [folinic acid /
5FU /irinotecan / oxaloplatin]. Furthermore, unfortunately, not all patients would benefit from this
therapy as personalised predictive biomarkers are lacking. Potential biomarkers include regulators
of drug metabolism and activity, such as the enzyme of 5-FU catabolism—dihydropyrimidine
dehydrogenase (DPD), and the target enzyme thymidylate synthase (TS) [12]. More recently, a
number of biological/oncogenic targets, in particular, the epidermal growth factor receptor (EGFR),
have received attention [13–15]. However, EGFR blockade and anti-angiogenic therapy trials were not
successful for treatment of PDAC [11].
Without doubt, there is an urgent need to develop reliable novel biomarkers for PDAC both to aid
diagnosis and to serve as therapeutic targets. One such promising functional biomarker is Wnt-11,
a member of a family of secreted proteins that regulate tissue growth and morphogenesis during
development. It has previously been reported that Wnt-11 also plays a significant pathophysiological
role in major carcinomas, e.g., cancers of prostate, cervical, ovarian and colon and controls
neuroendocrine differentiation [16–19]. Wnt-11 is downstream of TGFβ—shown previously to be one of
the triggers of epithelial-mesenchymal transition (EMT) and chemoresistance [20–22]. TGFβ signalling
has been shown to be involved in PDAC progression, promoting genomic instability, neoangiogenesis,
immune evasion, cell motility and metastasis in late-stage disease [23,24]. Moreover, TGFβ ligands
are commonly overexpressed in PDAC and can promote EMT, enabling cancer cells to gain invasive
properties and initiating metastasis [25,26]. Another frequently observed characteristic of aggressive
carcinomas is expression of molecular markers normally associated with neurones (e.g., [27–29]).
However, whether Wnt-11 controls EMT and/or expression of neuronal markers (NEMs) in PDAC is
unknown. It is also not known if Wnt-11 is involved in cellular invasiveness in PDAC and how it may
relate to survival of patients. The present study aimed to elucidate these aspects first in vitro and then,
in a clinical setting, in vivo.
2. Materials and Methods
2.1. Cell Lines
Three PDAC cell lines, BxPC-3, MiaPaca-2 and Panc-1, were selected to study and purchased from
ATCC. The cells maintained at 37 ◦C and 5% CO2 and were grown either in Dulbecco’s Modified Eagle
Medium (DMEM) with high glucose and stable glutamine (for MiaPaCa-2 and Panc-1) or Roswell Park
Memorial Institute medium (RPMI) with high glucose and stable glutamine (for Bx-PC3) supplemented
with 10% FBS.
2.2. Patient Samples
Fresh frozen PDAC tissues (n = 111), with matched normal adjacent tissues from the same
patients, were collected following surgical resection at the Beijing Cancer Hospital and were stored.
Clinicopathological factors, such as age, sex, histological type, TNM stage, and lymph node metastasis
were recorded and stored in the patients’ database. The local ethics committee approved all the
protocols and consent was obtained from the patients. Wnt-11 mRNA levels were quantified using
real-time qPCR (qRT-PCR), with cytokeratin 19 (CK19) as the normalizing (“house-keeping”) gene for
the tissue samples. Fresh-frozen pancreatic adenocarcinoma tissues (n = 202), along with matched
normal tissue from the same patients, were collected immediately after surgical resection at the
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Beijing Cancer Hospital and were stored at the Tissue Bank of Peking University Oncology School.
Clinicopathological factors such as age, sex, histological type, TNM stage, and lymph node metastasis,
were recorded and stored in the patient database. All protocols were reviewed and approved by the
local Ethics Committee (MTA01062008) and consent was obtained from the patients. Patients were
recruited between January 2002 and December 2009 and were routinely followed up.
2.3. Isolation of RNA, cDNA and qRT-PCR
mRNA was isolated using an mRNA extraction kit according to the manufacturer’s
instructions (Qiagen, Germantown, MD, USA). RNA quality and quantity were assessed NanoDrop
Spectrophotometer at 260 nm and 280 nm absorbance. cDNA was generated and the following genes
were studied (corresponding primer sequences given in references in parentheses): Wnt-11, NSE, Hes6,
Neuro D [16]; Nanog [30]; Vim, Snail, Twist, E-cadherin (CDH1) [31]. qRT-PCR analysis was done using
Taq SYBR Green premix (Qiagen, Germantown, MD, USA) and the following conditions were used:
95 ◦C for 15 minutes, 40 cycles at 95 ◦C for 15 seconds, 60 ◦C for 1 minute and a dissociation stage (95 ◦C
for 15 seconds, 60 ◦C for 1 minute, 95 ◦C for 15 seconds, 60 ◦C for 15 seconds). Relative levels of mRNA
expression were calculated using the Comparative CT/2−∆∆CT method [32] with RNA polymerase II
(RPII) as the house-keeping gene for the in-cell-line-based studies [33].
2.4. RNA Sequencing
Total RNA was isolated from cells by using Trizol (Sigma, Gillingham, Dorest. UK). The reverse
transcription to cDNA was performed with IonAmpliseqTM Transcriptome Human Gene Expression
kit (Life Technologies). We then used the Human Gene Expression Core Panel primer set (Life
Technologies) to prepare small amplicon gene expression libraries targeting 20,000 genes (95% of
the RefSeq gene database). The cDNA amplicon libraries (125–300 bp) were ligated to adapters and
amplified using IonXpress RNA-seq barcoded primers (5′). cDNA libraries were clonally amplified
using an Ion PI template OT2 200 kit (Life technologies, USA) on an Ion OneTouch2 system (Life
technologies) as per the manufacturer’s instructions. Samples were processed using the Ion Proton
200 sequencing kit and loaded onto a P1 chip and sequenced on an Ion Proton (Life technologies)
using default parameters (single-end, forward sequencing). Base calling, adaptor trimming, barcode
deconvolution, alignment and Ampliseq gene expression analysis was performed on Torrent Suite
version 3.6 (Life technologies).
2.5. siRNA
Panc-1 cells were transfected with siRNA and non-targeting control (Dharmacon, Lafayette,
CO, USA). siRNA transfections were performed according to the manufacturer’s protocols using
DharmaFECT 2 (Dharmacon, Lafayette, CO, USA). Briefly, Panc-1 cells were seeded in 6-well plates for
48 hours before transfection using ON-TARGETplus SMARTpool WNT-11 siRNA or ON-TARGETplus
non-targeting pool (Dharmacon, Lafayette, CO, USA). Transfected cells were used for RNA extraction
(after 48 h) or cell invasion and immunostaining assays (72 h).
2.6. Invasion and Proliferation Assays
Details of cell invasion assay were as reported previously [16]. Briefly, 5 × 105 cells (transfected or
control) were plated on Matrigel-coated transwell filters (BD Biosciences) in a chemotactic gradient
of 1:10% FBS. After 16 hours, the total number of invaded cells was determined by MTT assay and
this was confirmed by crystal violet assay. In parallel, the same number of cells plated and incubated
for 16 h to determine the effect of the cell proliferation by MTT assay. Invasion and proliferation
were presented as “Invasion” and “Proliferation”, i.e., percentage (%) of the readings for invaded
cells/original cell number.
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2.7. Immunostaining
Immunocytochemistry was performed as described previously [26]. Wnt-11 silenced Panc-1 and
control (cell transfected with scrambled siRNA) cells were fixed in 4% paraformaldehyde for 15 minutes,
blocked with 5% BSA/PBS for 30 minutes and incubated with goat anti-Wnt-11 (1:20) overnight at 4 ◦C.
Alexa Fluor®488 goat anti-mouse IgG (H + L) (Invitrogen) was used as secondary antibody (1:500,
60 minutes at room temperature) and nuclei were counterstained using 1.0 µM TO-PRO-3 (Invitrogen).
2.8. Survival Analysis
Survival data was obtained on 22nd of Oct 2019 from Human Protein Atlas website: https:
//www.proteinatlas.org/ENSG00000085741-WNT11/pathology/pancreatic+cancer#Location Wnt-11
expression of total 176 patients was analysed, (low expression; n = 121 and high expression; n = 55) and
Kaplan–Meier survival estimators examined the prognosis of each group of patients, and the survival
outcomes of the two groups were compared by log-rank tests [34].
2.9. Data Analysis
All data were analysed as means ± standard errors. Statistical significance was determined
using Student’s t-test or ANOVA with Newman–Keuls post-hoc analysis, as appropriate. Results were
considered significant for p < 0.05.
3. Results
Three sets of results are presented. First, we describe the Wnt-11 mRNA profile of three different
PDAC cell lines and using siRNA, we demonstrate that Wnt-11 controls the expression of several
biomarkers associated with metastasis. Secondly, we show that silencing Wnt-11 expression results
in significant inhibition of cellular invasiveness. Thirdly, we demonstrate that Wnt-11 mRNA levels
were significantly higher in clinical samples of PDAC compared with matched normal tissues. Overall,
these data suggest that Wnt-11 is involves in the pathophysiology of PDAC.
3.1. Wnt-11 mRNA Expression Profiling
Wnt-11 mRNA expression in three different PDAC cell lines (BxPC-3, Panc-1 and MiaPaCa-2)
was quantified using qRT-PCR. The BxPC-3 cell, which has the most epithelial properties, expressed
relatively the least Wnt-11 mRNA and this was used as a “baseline’ (Figure 1A). Expression was
significantly higher in MiaPaca-2 cells (460 + 11% cf. BxPC-3 cells; n = 6; p < 0.01; Figure 1A). Panc-1 cells
expressed relatively the highest level (2600 + 15 % cf. BxPC-3 cells; n = 6; p < 0.01; Figure 1A; statistical
significance was determined using Student’s t-test). RNA sequencing confirmed that Wnt-11 mRNA
expression in Panc-1 cells was higher than MiaPaca-2 cells (Table S1). Similar increases were found for
NSE, Hes6, Nanog, Snail and Twist (Table S1). In the following in vitro experiments, the Panc-1 cell
line was adopted as a model due to its high Wnt-11 expression.
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Figure 1. Wnt-11 mRNA relative expression profile in Bx-PC3, Panc-1 and MiaPaca-2 cells, and Wnt-
11 siRNA on Panc-1 cells. (A) Real-time PCR result of Wnt-11 relative mRNA expression. Data are 
plotted as fold-differences relative to the Bx-PC3 cell Wnt-11 mRNA expression level after 
normalising with housekeeping gene (RPII) level. Panc-1 cells express the highest amount of Wnt-11 
mRNA (folds more than Bx–PC3; n = 6; p < 0.01) among three pancreatic cancer cell lines and Wnt-11 
siRNA reduces the expression 4.52-fold (light grey bar; n = 6; p = 0.011). All data were analysed as 
means ± standard errors. Statistical significance was determined using Student’s t-test or ANOVA 
with Newman–Keuls post-hoc analysis were used, as appropriate. (B and C) Immunostaining for 
Wnt-11 (green) and To-Pro (blue) in Panc-1 cells transfected with Wnt-11siRNA. (B) Control. (C) Wnt-
11 siRNA for 48 hours. Scale bar, 20 µm (applicable to both panels). 
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Silencing Wnt-11 in Panc-1 cells led to a reduction in mRNA expression to 22 + 2% of the control 
transfection, (n = 6; p < 0.05; Figure 1A). This was confirmed qualitatively at the protein level by 
immunocytochemistry (Figure 1B,C). We then determined whether Wnt-11 was involved in 
expression of biomarkers associated with metastasis (Figure 2). Two sets of such biomarkers were 
studied, those relating to neuronal characteristics and EMT [35,36]. As regards NEMs, Wnt-11 
silencing led to decreases of the following (percentage reduction according to the control transfection 
that was used as a ‘baseline’ and presented as 100% and statistical significance was determined by 
using Student’s t-test): NSE (53 + 2), NeuroD (89 + 2) and Hes6 (52 + 4); in addition, the stem cell 
marker Nanog was reduced to 94 + 2 (n = 6; p < 0.01 for all; Figure 2A). Initial qRT-PCR results 
suggested that Wnt-11 and E-cadherin mRNA levels were inversely correlated in PDAC cells. Indeed, 
following the Wnt-11 siRNA treatment in Panc-1 cells, the level of E-cadherin increased to 529 + 3% 
(n = 6; p < 0.01). In contrast, the other three EMT markers studied all showed decreases to the following 
percentages: Snail (73 + 4), Vim (83 + 3) and Twist (84 + 3) (n = 6; p < 0.01 for all; Figure 2B). Taken 
together, all results are consistent with Wnt-11 controlling EMT [22,37] and being involved in the 
promotion of neuronal characteristics [16,37,38]. 
Figure 1. Wnt-11 mRNA relative expression profile in Bx-PC3, Panc-1 and MiaPaca-2 cells, and Wnt-11
siRNA on Panc-1 cells. (A) Real-time PCR result of Wnt-11 relative mRNA expression. Data are plotted
as fold-differences relative to the Bx-PC3 cell Wnt-11 mRNA expression level after normalising with
housekeeping gene (RPII) level. Panc-1 cells express the highest amount of Wnt-11 mRNA (folds more
than Bx–PC3; n = 6; p < 0.01) among three pancreatic cancer cell lines and Wnt-11 siRNA reduces the
expression 4.52-fold (light grey bar; n = 6; p = 0.011). All data were analysed as eans ± standard
errors. Statistical significance was determined using Student’s t-test or ANOVA with Newman–Keuls
post-hoc analysis were used, as appropriate. (B,C) Immunostaining for Wnt-11 (green) and To-Pro
(blue) in Pa c-1 cells transfected with Wnt-11siRNA. (B) Control. (C) Wnt-11 siRNA for 48 hours. Scale
bar, 20 µm ( pplicable t both panels).
3.2. Effects of Silencing Wnt-11 on Biomarkers Associated with Metastasis
Silencing Wnt-11 in Panc-1 cells led to a reduction in mRNA expression to 22 + 2% of the control
transfection, (n = 6; p < 0.05; Figure 1A). This was confirmed qualitatively at the protein level by
immunocytochemistry (Figure 1B,C). We then determined whether Wnt-11 was involved in expressi n
of biomarkers associated with metastasis (Figure 2). Two sets of s ch biomarkers were studied, those
relati g to neuronal characteristics and EMT [35,36]. As regards NEMs, Wnt-11 sile cing led to
decreases of the following (percentage reduction according to the control transfection that was used
as a ‘baseline’ and presented as 100% and statistical significance was determined by using Student’s
t-test): NSE (53 + 2), NeuroD (89 + 2) and H s6 (52 + 4); in addition, the stem cell marker Nanog
was reduce to 94 + 2 ( = 6; p < 0.01 for all; Figure 2A). Initi l qRT-PCR results suggested that
W t-11 and E-cadherin mRNA levels were inversely correlated in PDAC cells. Indeed, following the
Wnt-11 siRNA treatment in Panc-1 cells, the level of E-cadherin increased to 529 + 3% (n = 6; p < 0.01).
In contrast, the other three EMT markers studied all showed decreases to the following percentages:
Snail (73 + 4), Vim (83 + 3) and Twist (84 + 3) (n = 6; p < 0.01 for all; Figure 2B). T k n t gether, all
results are consiste t with Wnt-11 controlling EMT [22,37] and being involved in the promotion of
neuronal characteristics [16,37,38].
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Figure 2. Wnt-11 promotes epithelial-mesenchymal transition (EMT) and neuronal differentiation in
Panc-1 cells line. (A) qRT-PCR for NSE, NeuroD, Hes6 and Nanog relative mRNA expressions after
transfectio of Panc-1 cells either with scrambled or W t-11 siRNA after 48 hou s. W t-11 siRNA.
(B) qRT-PCR for EMT markers; Ecad, Snail, Vi and Twist relative mRNA expressions after transfection
of Panc-1 cells either with scrambled or Wnt-11 siRNA after 48 hours. NSE, NeuroD, Hes6 and
Nanog mRNA expressions and they were reduced after silencing Wnt-11 (53%, 89%, 51.5% and 94%
respectively; n = 6; p < 0.05 for all). Wnt-11 siRNA increased Ecad mRNA expression 5.29-fold in
Panc-1 cells (n = 6; p = 0.02). ther E T markers, such as Snail, Vim and Twist expressed in Panc-1 and
MiaPaca-2 cells and this expr ssion was reduced b t- 1 siRNA in Pan -1 cells (Fig 2B; min 70%
reduction for all, n = 6; p < 0.05). Statistical signific ce as d termined using Student’s t-test and
ANOVA were used.
3.3. Effect of Silencing Wnt-11 on Cellular Invasiveness
The invasiveness of Panc-1 cells was studied in Boyden chambers with Matrigel (Figure 3).
Cells demonstrated a noticeable invasion over 16 h. Silencing Wnt-11 resulted in significant suppression
of invasiveness by 23 + 2% (n = 3; p < 0.01; Figure 3A). As exp cted, there was no change in the
cell number over the 16 hours (Figure 3B). Thus, Wnt-11 could promote invasiveness independently
of proliferation.
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 Figure 3. Functional evidence for Wnt-11-induced reduction of Matrigel invasion on Panc-1 cell
lines. Panc-1 cells were transfected for 72 hours with control or Wnt-11 siRNAs, plated on Matrigel
coated transwell filters and the extent of invasion determined after 16 hours. (A) Wnt-11 siRNA
decreased invasion by 23% (n = 3; p = 0.02). The results are plotted as Invasion Index (InvI, %), which
is the percentage of invaded cells compared to the total number of cells seeded. (B) The total cell
number/proliferation did not change during the course of the experiment (n = 3; p > 0.05). All data
were analysed as means ± standard errors.
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3.4. Expression in Biopsies
We also determined the Wnt-11 mRNA levels in clinical samples of PDAC and compared these
with ‘matched’ control tissues (Figure 4A). In direct agreement with the in vitro data, the average
level in PDAC was significantly (four-fold) higher than the matching controls (p = 0.02; n = 111).
We then questioned any association between the Wnt-11 mRNA expression and TNM stage (Figure 4B).
Patient samples classified as T1, expressed the least Wnt-11. This was significantly (1931 + 125%)
higher for T2 (p = 0.04). This increase was maintained for T3 and T4 with no further change (p > 0.05
for T3 and T4 cf. T2 and T3 cf. T4; Figure 4B).
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samples. (A) In total, 111 pairs of tumour and adjacent control tissues were studied and Wnt-11
expression (relative) appeared to be increased in the tumo r tiss e compared t adjacent normal tissues
(p = 0.02). (B) A high level of Wnt-11 expressio (relativ ) was found in patients classifie ccordi g to
T staging (p < 0.05 for T1 vs T2 or T3 or T4; T2 vs T3 or T3 vs T4 p > 0.05). All data were a alysed s
mean ± standard errors.
4. Discussion
The main results are as follows: 1) Wnt-11 mRNA expression occurred commonly in PDAC
cell lines and was significantly higher in PDAC compared with matched control tissues; 2) Wnt-11
promoted NEM expression and EMT as well as cellular invasiveness without affecting proliferative
activity; 3) an increased level of Wnt-11 expression in PDAC patients was associated with TNM stage
as a relatively early event.
4.1. Wnt-11 Expression in PDAC Cells and Tissues: Control of NEMs, EMT and Invasiveness
We showed that Wnt-11 mRNA is expressed in three different PDAC cell lines. In agreement with
this, Wnt- 1 mRNA was present in PDAC tiss es and this was at a significantly higher level compared
with corresponding normal tissues. The in vitro pathophysiological role of the Wnt-11 was investigated
by a siRNA approach. Thus, silencing Wnt-11 suppressed the expression of a range of biomarkers
associated with metastasis, especially NEMs and those involved in EMT. Such effects suggest that
Wnt-11 would promote PDAC aggressiveness and this was confirmed by Matrigel invasion assays.
Interestingly, the inhibitory effect on invasion was seen without any change in proliferative activity,
which is consistent with the notion that primary and secondary tumourigenesis (i.e., proliferation vs.
invasion) can be controlled differently, even independently [16,39].
Overall, members of the Wnt family of secreted proteins are known to play a significant role
in determining the “stemness”, EMT, acquisition of neuronal characteristics and invasiveness of
carcinomas [16,17,20]. The level of Wnt-11 mRNA expression correlates strongly with levels of
neuroendocrine differentiation in cancers of the prostate and breast [16,39]. Wnt-11 also controls
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expression of a neurone-specific enolase, which drives neuronal differentiation and enhanced
cell viability and migration in prostate cancer [16]. These findings constitute strong evidence
that Wnt-11 promotes migratory behaviour of cells, including multipotent stem/progenitor cells,
during development and cancer progression, including cancers of breast, prostate, colon and
cervix [16,19,39–42]. This has now been extended to PDAC in vitro and in vivo. Thus, Wnt-11 seems
to play a consistent role in the pathophysiology of cancer. Indeed, Wnt-11 is evolutionarily a highly
conserved protein, regulated by TGFβ and calcium in a wide variety of cell types [20,42,43].
4.2. Mechanistic Aspects
At present, the mechanism(s) underlying the role of Wnt-11 in promoting cancer (including
PDAC) cell invasiveness is/are unknown. Overall, Wnt-11 is a member of the non-canonical Wnt
family, which is associated with three different signalling pathways: Planar cell polarity (PCP), Ca2+
and other β-catenin/TCF independent events [44]. Here, insights can be obtained by focusing on Ca 2+
signalling. It is known that the Frizzled family of Wnt receptors, including Wnt-11, can elicit the release
of intracellular Ca2+ [42]. In turn, the rise in Ca2+ can promote invasiveness by enhancing both cellular
motility and proteolysis, integral to the Boyden chamber (Matrigel) assay. For example, Ca2+-activated
K+ channels were shown to enhance motility of Mia-Paca cells [45]. Another pathway could involve
activation of ROCK [46,47]. As regards proteolysis, matrix metalloproteinases (MMPs) are known
to be upregulated in response to non-canonical Wnt stimulation during development and tissue
remodelling and promote cell migration [48,49]. Increased MMP (e.g., MMP-2, MMP-7 and MMP-9)
expression occurs frequently upon Wnt stimulation of tumour cell invasion [50–53]. There is also
substantial evidence for multi-modal regulation of MMPs by Ca2+ [53]. Consistently with the proposed
non-canonical Wnt-Ca2+ association, it has been shown that intracellular Ca2+ signalling can trigger
EMT induction in human cancers [54]. Moreover, TGF-β1 and Ca2+ have synergic effects in promoting
EMT and osteochondral differentiation via Wnt-11 and L-type calcium channels, respectively [22].
Further research is required to determine the precise role of Ca2+ signalling in the pathophysiology
of PDAC.
4.3. Wnt-11 Expression in PDAC and Survival
Our tissue analyses complement our in vitro data. Thus, in our cohort of paired human tissue
samples, the levels of Wnt-11 mRNA were significantly higher in PDACs compared to their respective
normal adjacent tissues. Furthermore, within this tissue set, expression was already high at TNM
stage II and maintained at stages III and IV. Previous work on different cancer types also suggested
that Wnt family members play a significant role in TNM staging [55,56]. These results are consistent
with Wnt-11 expression being a relatively early event in PDAC development/progression. Some of the
critical data obtained from the Human Protein Atlas database [34] is that it includes 176 samples from
different grading stages at PDAC. All data indicate that higher-grade patients showed diminished
survival analysis with up-regulated Wnt-11 expression. Five-year survival for the “higher” group
was 26%, compared with 31% for the group with lower Wnt-11 expression (p = 0.02, Figure 5). In the
first instance, these data give further credence to the results from the in vitro and tissue analyses.
More broadly, as noted above, since functional Wnt-11 expression occurs in other cancers as well, its
role in determining survival may be more widespread in oncology [57].
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5. Conclusions
In conclusion, our data are consistent with Wnt-11 occurring early in the development of PDAC
and controlling cellular expression of NEMs, EMT and invasiveness. More studies are needed to
compare Wnt-11 expression and its role in non-malignant pancreatic cell lines and tissues and its
function. Therefore, unsurprisingly, upregulation of Wnt-11 expression ultimately worsens patient
survival. Thus, Wnt-11 may be considered as a novel prognostic biomarker for PDAC. Since this is a
potential functional biomarker, inhibiting Wnt-11 expression and/or activity may also be of therapeutic
importance [58].
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